# IGSF11: A Novel Target for Cancer Immunotherapy

## TL;DR

This paper explores IGSF11 as a new target for cancer immunotherapy due to its role in suppressing T cell function through interaction with VISTA.

## Contribution

The paper systematically reviews IGSF11's structure, regulation, and interaction with VISTA as a novel immunotherapy target.

## Key findings

- IGSF11 is an inhibitory immune checkpoint molecule that interacts with VISTA to suppress T cell activity.
- Blocking IGSF11 or its interaction with VISTA shows potential for anti-tumor effects.
- IGSF11's expression and prognostic value vary across different cancer types.

## Abstract

免疫检查点阻断疗法在多种类型的肿瘤治疗中显示出显著的疗效，但其临床应用仍面临着如免疫应答率低及免疫相关不良事件的挑战。免疫球蛋白超家族成员11（identification of immunoglobulin superfamily 11, IGSF11）是一种抑制性免疫检查点分子，作为T细胞活化的V型免疫球蛋白结构域抑制因子（V-domain immunoglobulin suppressor of T cell activation, VISTA）的特异性配体，其通过IGSF11/VISTA轴抑制T细胞功能，有潜力成为免疫治疗肿瘤的新靶标。IGSF11广泛表达于多种恶性肿瘤中，其调控机制因肿瘤类型不同而存在差别。已有研究证明阻断IGSF11与VISTA结合或对IGSF11进行特异性抑制，可产生抗肿瘤作用。IGSF11与患者预后密切相关，但其在不同肿瘤中的预后价值不同。本文将对IGSF11的结构特征、表达调控机制、与VISTA的相互作用及其在肿瘤微环境中的作用进行系统概述。

Advances in targeted therapeutic agents for IGSF11 and VISTA